Archives
-
Self-Amplifying RNA Vaccines Improve Influenza Dose Sparing
2026-09-08
This 2026 study compared nucleoside-modified mRNA, self-amplifying RNA, and circular RNA vaccine approaches across influenza A and B models. Its central finding was that a low-dose trivalent self-amplifying RNA formulation produced durable antibody responses and complete protection against influenza B challenge in mice, where conventional mRNA showed weak protection.
-
Bromodomain Inhibitor, (+)-JQ1 Workflows
2026-09-08
Build better epigenetic experiments with (+)-JQ1 across AR-stratified cancer models, apoptosis assays, inflammatory signaling, and BRDT-focused reproductive biology. This guide emphasizes practical dosing, orthogonal readouts, formulation control, and the limits of translating BET biology between research domains.
-
Ivermectin: Mechanistic Rigor for Translational Research
2026-09-07
A thought-leadership guide to using Ivermectin as a broad-spectrum anti-parasitic research compound, with emphasis on mechanism-linked assays, compound integrity, translational decision points, and lessons from Gasdermin C research in pancreatic cancer.
-
Ruxolitinib (INCB018424) Workflow Guide
2026-09-07
Build a reproducible Ruxolitinib workflow that connects JAK1/2 target engagement with progenitor-cell, phospho-signaling, and high-dimensional immune readouts. The guide also shows how the compound can support mechanistic studies of myelofibrosis, oncogenic JAK2 fusion proteins, and combination immunotherapy without overstating preclinical evidence.
-
EdU Imaging Kits (Cy3): S-Phase Assay Guide
2026-09-05
EdU Imaging Kits (Cy3) convert DNA replication into a bright Cy3 signal without the DNA-denaturation step required by BrdU assays. This practical guide shows how to apply the method to microscopy, flow cytometry, and LmPLK1-linked insect gut research while avoiding common interpretation and optimization errors.
-
RESTRICT-seq Reveals Epigenetic Dependencies in SCC
2026-09-04
The preprint introduces RESTRICT-seq as a time-gated CRISPR screening strategy designed to separate resistance-associated gene functions from baseline fitness effects. Its application to SCC resistance highlights previously underappreciated epigenetic dependencies and provides a framework for prioritizing mechanistic and pharmacological validation.
-
Tiamulin (Thiamutilin): From Dose to Residue
2026-09-04
Tiamulin (Thiamutilin) is more than a pleuromutilin antibiotic: its species-dependent metabolism directly shapes pharmacology, residue analysis, and assay design. This evidence-based guide connects ribosomal targeting, PK/PD interpretation, UHPLC–Q/TOF metabolite profiling, and emerging anti-inflammatory research.
-
PA-824: From Prodrug to Respiratory Biology
2026-09-03
PA-824 is a bicyclic nitroimidazole derivative whose activity depends on both nitro-reduction and respiratory-state biology. This article translates recent pretomanid findings into practical assay decisions for tuberculosis research, combination testing, and mechanism-resolved interpretation.
-
KCNE4 Modulates Kv1.3 Blocker Pharmacology
2026-09-03
The reference study shows that KCNE4 changes Kv1.3 pharmacology by slowing intracellular Psora-4 inhibition without materially changing blocker affinity. This finding links leukocyte-specific channel architecture to assay kinetics and supports more realistic evaluation of Kv1.3 blockers in immune-cell research.
-
PDGF-BB, murine recombinant protein Guide
2026-09-02
A scenario-based guide to using PDGF-BB, murine recombinant protein in viability, proliferation, and cytotoxicity workflows. It explains how SKU P1048 supports assay design through defined activity, purity, endotoxin, reconstitution, and storage specifications.
-
Pyruvate Carboxylase, Ferroptosis, and NSCLC
2026-09-02
A 2026 Cancer Letters study identifies pyruvate carboxylase (PC) as a metabolic regulator of ferroptosis resistance in non-small cell lung cancer. The work connects ATP-dependent PC activity with AMPK suppression, AKT–mTOR-driven lipogenesis, and inhibition of the PPARα–ACSL4 pathway, while implicating DTX1 and USP51 as upstream regulators.
-
(Z)-4-Hydroxytamoxifen: A Mechanistic Assay Lens
2026-09-01
Explore (Z)-4-Hydroxytamoxifen as a high-affinity estrogen receptor probe and learn how nanoparticle research on redox biology can improve causal assay design. This article connects ER pharmacology, orthogonal readouts, delivery controls, and translational limitations without conflating distinct disease models.
-
AZD1480: Practical JAK2/STAT3 Assay Workflows
2026-09-01
Use AZD1480 to separate tumor-intrinsic JAK2/STAT3 survival signaling from broader immune effects after IDO1 blockade. This workflow covers cytokine stimulation, myeloma and solid-tumor assays, combination testing, and troubleshooting from stock preparation through pathway validation.
-
Tiamulin Metabolism Across Farm Animal Species
2026-08-31
This study mapped tiamulin biotransformation across rats, chickens, swine, goats, and cows using in vitro and in vivo models coupled with UHPLC–Q/TOF analysis. Its principal contribution is the identification of 26 metabolites, species-specific pathway differences, and candidate marker residues that can improve veterinary residue monitoring and food-safety assessment.
-
AZD1480 for Reliable JAK2/STAT3 Assays
2026-08-31
Learn how AZD1480 (SKU A4137) can help researchers distinguish JAK2/STAT3-driven survival from nonspecific assay variation in viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers mechanism, solvent control, compartment-resolved experiments, data interpretation, and practical product-selection criteria.